Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 42.00
Bid: 41.50
Ask: 42.50
Change: -0.30 (-0.71%)
Spread: 1.00 (2.41%)
Open: 41.75
High: 41.70
Low: 41.70
Prev. Close: 42.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sch 1 - Readybuy PLC

21 Jul 2006 10:15

AIM21 July 2006 ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH AIM RULE 2 ALL APPLICANTS MUST COMPLETE THE FOLLOWING: COMPANY NAME:Readybuy plc COMPANY ADDRESS:Television House, 10-12 Mount Street, Manchester COMPANY POSTCODE:M2 5NT COUNTRY OF INCORPORATION:England and Wales COMPANY BUSINESS OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTMENT STRATEGY TO BE DISCLOSED INACCORDANCE WITH SCHEDULE 2, PARAGRAPH (J) OF THE AIM RULES:Since the Readybuy group's trading activities were terminated in July 2005, the directors of Readybuy have beenexploring the future options available to the Company. The Company's investing strategy is to acquire a companyinvolved in developing enabling technologies, particularly in the defence and bio-chemistry sectors. The Boardbelieves that the proposed acquisition of Avacta meets this investment strategy. Avacta was spun-out from the University of Leeds in January 2004 by its current management team as a biophysicscompany, with the aim of combining the disciplines of physics and biology to develop innovative technologies toaddress needs in the homeland security, pharmaceutical and clinical diagnostic markets. Avacta has two core activities: the development of detection technology platforms designed to meet the needs ofits target markets; and the provision of analytical services relating to the chemical and physical analysis ofmaterials to a range of companies, principally in the pharmaceutical, healthcare and personal care sectors. DETAILS OF SECURITIES TO BE ADMITTED (i.e. where known, number of shares, nominal value and issue price to whichit seeks admission and the number and type to be held as treasury shares):644,857,446 ordinary shares of 0.1p each on First Admission 24,469,898 ordinary shares of 0.1p each on Second AdmissionCAPITAL TO BE RAISED ON ADMISSION:£1,012,500 before expenses, by means of a placing of 45,000,000 ordinary shares of 0.1p each at 2.25p per share FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS:Directors: Daron Ross Lee (non-executive Chairman) Professor David Alastair Maclaughlin Smith (non-executive director and proposed Chief Executive followingAdmission) Proposed Directors: Dr. Gwynfor Owen Humphreys (proposed non-executive Chairman)Dr. Simon Webster (proposed Chief Scientific Officer)Dr. Kurt Justin Baldwin (proposed Chief Technology Officer)Timothy James Sykes (proposed Chief Financial Officer and proposed Company Secretary)Professor Anthony William Robards (proposed non-executive director)Alan John Aubrey (propose non-executive director) PERSON(S) INTERESTED IN 3% OR MORE OF THE ISSUER'S CAPITAL, EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITALBEFORE AND AFTER ADMISSION:Before: Robert Quested (29.76%)Christopher Potts (16.96%)Stephen James (16.09%)Robert Quested, Christopher Potts and Stephen James are also interested in warrants to subscribe for 18,500,000;10,500,000; and 10,000,000 Ordinary Shares respectively. On Admission: Robert Quested (8.93%)Christopher Potts (3.15%)Stephen James (2.99%) The members of the Existing Concert Party, as at the date of this document, together hold 83.71% of the issuedshare capital of the Company, and will, immediately following the Placing and Admission hold 19.84 % thereof.The members of the New Concert Party (being the vendors of Avacta), as at the date of this document, togetherhold 0.96% of the issued share capital of the Company, and will, immediately following the Placing and Admissionhold 74.88% thereof. NAMES AND ADDRESSES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES:None ANTICIPATED ACCOUNTING REFERENCE DATE:30 April EXPECTED ADMISSION DATE:8 August 2006 (First Admission)9 August 2006 (Second Admission) NAME AND ADDRESS OF NOMINATED ADVISER:WH Ireland Limited11 St James's SquareManchesterM2 6WH NAME AND ADDRESS OF BROKER:WH Ireland Limited11 St James's SquareManchesterM2 6WH DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENTTHAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES:Copies of the admission document containing full details about the applicant and the admission of its securitieswill be available free of charge to the public until at least one month after admission at the offices of:- WH Ireland Limited11 St James's SquareManchesterM2 6WH DATE OF NOTIFICATION:21 July 2006 NEW/ UPDATE (see note):New This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
23rd May 20247:00 amRNSSuccessful Completion of First Cohort
30th Apr 20247:01 amRNSFull Year Results
30th Apr 20247:00 amRNSBoard Change
26th Apr 20249:51 amRNSBlock listing Interim Return REPLACEMENT
26th Apr 20247:00 amRNSBlock Listing Six Monthly Return
23rd Apr 20249:43 amRNSBlock Listing Application to AIM
23rd Apr 20247:00 amRNSNotice of Results
22nd Apr 202412:14 pmRNSIssue of Equity and Total Voting Rights
9th Apr 20245:00 pmRNSAvacta Reports Data at the AACR Annual Meeting
8th Apr 20247:00 amRNSAVA6000 Abstract Release by AACR
28th Mar 20244:00 pmRNSInvestor Webinar
21st Mar 20247:00 amRNSUpdate on AVA6000 Phase 1a Clinical Trial Progress
18th Mar 20241:26 pmRNSResult of General Meeting
6th Mar 20247:00 amRNSAvacta Announces AVA6000 Poster at AACR
5th Mar 20247:00 amRNSResult of REX Retail Offer
29th Feb 20247:00 amRNSResult of Placing
28th Feb 20244:42 pmRNSProposed REX Retail Offer
28th Feb 20244:41 pmRNSProposed Fundraise to progress Therapeutics
16th Feb 20247:00 amRNSShare Incentive Plan/Issue of Equity
22nd Jan 202410:51 amRNSIssue of Equity and Total Voting Rights
19th Jan 20247:00 amRNSAppointment of Christina Coughlin
19th Dec 20237:00 amRNSAppointment of Chief Business Officer
13th Dec 20237:00 amRNSALS-6000-101 Phase 1a Study Data
4th Dec 20237:00 amRNSShareholder update to review AVA6000 Phase 1a data
27th Oct 20237:00 amRNSBlock Listing Six Monthly Return
23rd Oct 20231:30 pmRNSIssue of Equity and Total Voting Rights
18th Oct 20231:00 pmRNSBlock Listing Application to AIM
5th Oct 20237:00 amRNSAvacta to present at AACR-NCI-EORTC conference
28th Sep 20237:00 amRNSInterim Results for the Period Ending 30 June 2023
20th Sep 20232:00 pmRNSIssue of Equity and Total Voting Rights
20th Sep 20237:01 amRNSPeel Hunt Appointed as Joint Broker
20th Sep 20237:00 amRNSAppointment Dr.Christina Coughlin as a consultant
19th Sep 20237:00 amRNSSuccessful Completion of Sixth Dose Escalation
6th Sep 20237:00 amRNSNotice of Results
21st Jul 20233:00 pmRNSIssue of Equity and Total Voting Rights
28th Jun 202311:00 amRNSResult of Annual General Meeting
28th Jun 20237:00 amRNSAnnual General Meeting and Shareholder Event
21st Jun 20237:00 amRNSCompletion of Fifth Dose Escalation in AVA6000
19th Jun 20237:01 amRNSDirector Appointment
19th Jun 20237:00 amRNSStatement regarding market speculation
8th Jun 20237:00 amRNSAGM and Shareholder Event Detailed Agenda
5th Jun 20237:00 amRNSSecond Milestone in AffyXell Joint Venture
2nd Jun 20237:00 amRNSPosting of Annual Report and Notice of AGM
1st Jun 20237:00 amRNSAvacta acquires Coris Bioconcept
27th Apr 20237:00 amRNSBlock Listing Six Monthly Return
27th Apr 20237:00 amRNSFirst Patient Dosed in the US in AVA6000 Phase 1
25th Apr 20237:00 amRNSPreliminary Results
21st Apr 20232:49 pmRNSIssue of Equity and Total Voting Rights
17th Apr 20237:00 amRNSAVA3996 data poster presented at AACR
6th Apr 20237:00 amRNS1st US Clinical Investigator AVA6000 Sites Opened

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.